These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32102539)

  • 61. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
    Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
    Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
    Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    Wang RX; Chen S; Huang L; Shao ZM
    BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
    He J; Peng R; Yuan Z; Wang S; Peng J; Lin G; Jiang X; Qin T
    Med Oncol; 2012 Jun; 29(2):406-10. PubMed ID: 21264529
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
    Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
    Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Kinesin Family Member C1 (KIFC1/HSET) Underlies Aggressive Disease in Androgen Receptor-Low and Basal-Like Triple-Negative Breast Cancers.
    Jinna N; Yuan YC; Rida P
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003261
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
    Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer.
    Lyalkin SA; Verevkina NO; Alekseyenko OO; Syvak LA
    Exp Oncol; 2020 Jun; 42(2):140-143. PubMed ID: 32602289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
    Liu L; Li XR; Hu YH; Zhang J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India.
    Chandra D; Suresh P; Sinha R; Azam S; Batra U; Talwar V; Kumar K; Mehta A
    Asian Pac J Cancer Prev; 2016; 17(6):2995-9. PubMed ID: 27356724
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression.
    Bae MS; Park SY; Song SE; Kim WH; Lee SH; Han W; Park IA; Noh DY; Moon WK
    Eur Radiol; 2015 Feb; 25(2):419-27. PubMed ID: 25224727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
    Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
    Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.